MYO logo

Myomo, Inc. Stock Price

NYSEAM:MYO Community·US$41.7m Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 42 Fair Values set on narratives written by author

MYO Share Price Performance

US$1.03
-1.23 (-54.42%)
US$10.00
Fair Value
US$1.03
-1.23 (-54.42%)
89.7% undervalued intrinsic discount
US$10.00
Fair Value
Price US$1.03
AnalystHighTarget US$10.00
AnalystLowTarget US$1.10
AnalystConsensusTarget US$5.00

MYO Community Narratives

·
Fair Value US$10 89.7% undervalued intrinsic discount

Expanding Reimbursement Access And New Products Will Transform Long Term Prospects

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
·
Fair Value US$1.1 6.4% undervalued intrinsic discount

Medicare Access And Margin Pressures Will Dominate Before Long-Term Rehabilitation Demand Emerges

1users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
·
Fair Value US$5 79.4% undervalued intrinsic discount

Myoelectric Orthoses Adoption And International Reimbursement Expansion Will Support Long Term Upside Potential

0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
US$10
89.7% undervalued intrinsic discount
Profit Margin
4.04%
Future PE
200.2x
Price in 2029
US$12.74
US$5
79.4% undervalued intrinsic discount
Profit Margin
0.21%
Future PE
2.08kx
Price in 2029
US$6.37

Trending Discussion

Updated Narratives

MYO logo

MYO: Future Profitability Assumptions Will Balance Expanded Access And Share Authorization

Fair Value: US$1.1 6.4% undervalued intrinsic discount
1 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
MYO logo

Expanding Reimbursement Access And New Products Will Transform Long Term Prospects

Fair Value: US$10 89.7% undervalued intrinsic discount
1 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
MYO logo

Myoelectric Orthoses Adoption And International Reimbursement Expansion Will Support Long Term Upside Potential

Fair Value: US$5 79.4% undervalued intrinsic discount
3 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Reasonable growth potential with adequate balance sheet.

3 Risks
2 Rewards

Myomo, Inc. Key Details

US$41.2m

Revenue

US$14.0m

Cost of Revenue

US$27.2m

Gross Profit

US$42.3m

Other Expenses

-US$15.1m

Earnings

Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
n/a
-0.39
65.96%
-36.69%
121.4%
View Full Analysis

About MYO

Founded
2004
Employees
195
CEO
Paul Gudonis
WebsiteView website
myomo.com

Myomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States, Germany, and internationally. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient’s weak or paralyzed arm to enable and improve functional activities of daily living. It also provides MyoPro 2 that includes control technology, configuration software and user interface, and pop-out battery for extended use of the brace; MyoPro2+, which comprises 3D printed orthotics capability, software enhancements, and a design for donning and doffing of the device; MyoGames, a virtual training platform; and MyoPro 2x Video Library. In addition, the company offers MyoCare, a post-delivery program that provides follow-up care with clients, therapists, and referral sources; MYOMO; MyoPal; and MyoCoach. Its products are designed to help adults and adolescents with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury, and other neurological disorders. The company sells its products through various sales channels, including orthotics and prosthetics providers, veteran’s administration, and distributors. Myomo, Inc. was incorporated in 2004 and is headquartered in Burlington, Massachusetts.

Recent MYO News & Updates

Narrative Update Jun 26

MYO: Future Profitability Assumptions Will Balance Expanded Access And Share Authorization

Analysts have trimmed their fair value estimate for Myomo from $2 to about $1.10, citing updated assumptions that include a different outlook for revenue growth, a much higher projected future P/E multiple and a sharply lower expected profit margin. What’s in the News for Myomo Myomo scheduled its 2026 Annual Meeting of Stockholders for June 25, 2026, and proposed amending its certificate of incorporation to increase authorized common shares to 100,000,000 shares.

Recent updates

No updates